$77.06
$103.26
--><!-- Ellie Rose Mattoon1, Radames JB Cordero2and Arturo Casadevall21Krieger School of Arts and Sciences, Johns Hopkins University Baltimore, Maryland, USA2Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, North Wolfe Street, Baltimore, USA Part of the book: The Book of Fungal Pathogens Abstract The physiological factors of COVID-19 infection and the environmental factors of treatment have predisposed a larger patient population to fungal infections. In this review, we provide an overview of the three most frequently documented fungal infections associated with COVID-19: aspergillosis, mucormycosis, and candidemia. For all three secondary infections, we review the literature making efforts to determine the incidence of infection, physiological or environmental causes of co-infection with COVID-19, and the mortality of infection both with and without COVID-19. These infections vary in their etiology in association with COVID-19 infection, in addition to their recommended treatments and mortality. Ultimately, we demonstrate the importance of early diagnosis of secondary infections and the proper identification of fungal pathogens for treatment purposes, while also highlighting research gaps in this new field. Keywords: COVID-19, secondary fungal infections, COVID-19 associated pulmonaryaspergillosis (CAPA), COVID-19 associated mucormycosis (CAM), COVID-19 associated candidemia (CAC) References [1] WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard withVaccination Data [Internet]. [cited 2022 Mar 13]. Available from: https://covid19.who.int/.[2] Bsmller, H., Matter, M., Fend, F., and Tzankov, A. (2021).The pulmonary pathology of COVID 19. Virchows Arch., Jan, 478(1), 137150.[3] Morgulchik, N., Athanasopoulou, F., Chu, E., Lam, Y., and Kamaly, N. (2022). Potential therapeuticapproaches for targeted inhibition of inflammatory cytokines following COVID-19 infection-inducedcytokine storm. Interface Focus., Feb 6, 12(1), 20210006.[4] Delavari, S., Abolhassani, H., Abolnezhadian, F., Babaha, F., Iranparast, S., Ahanchian, H., et al.(2021). Impact of SARS-CoV-2 Pandemic on Patients with PrimaryImmunodeficiency. J Clin Immunol., Feb, 41(2), 345355.[5] Tsiodras, S., Samonis, G., Boumpas, D. T., and Kontoyiannis, D. P. (2008). Fungal infectionscomplicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc., Feb, 83(2), 181194.[6] Casadevall, A. (2018). Fungal diseases in the 21st century: the near and far horizons.Pathog Immun., Sep 25, 3(2), 183196.[7] Vallabhaneni, S., Mody, R. K., Walker, T., and Chiller, T. (2016). The global burden of fungal diseases.Infect Dis Clin North Am., Mar, 30(1), 111.[8] Noreen, S., Maqbool, I., and Madni, A. (2021). Dexamethasone: Therapeutic potential, risks, and futureprojection during COVID-19 pandemic. Eur J Pharmacol., Mar 5, 894, 173854.[9] Giacobbe, D. R., Battaglini, D., Ball, L., Brunetti, I., Bruzzone, B., Codda, G., et al. (2020).Bloodstream infections in critically ill patients with COVID-19.Eur J Clin Invest., Oct, 50(10), e13319.[10] Rawson, T. M., Moore, L. S. P., Zhu, N., Ranganathan, N., Skolimowska, K., Gilchrist, M., et al.(2020). Bacterial and Fungal Coinfection in Individuals with Coronavirus: A Rapid Review to SupportCOVID-19 Antimicrobial Prescribing. Clin Infect Dis., 2020 Dec 3, 71(9), 24592468.[11] Srinivasan, A. Antibiotic Resistance (AR), Antibiotic Use (AU), and COVID-19. HHS, Feb 2021.[12] Rawson, T. M., Moore, L. S. P., Castro-Sanchez, E., Charani, E., Davies, F., Satta, G., et al. (2020).COVID-19 and the potential long-term impact on antimicrobial resistance. J Antimicrob Chemother.,Jul 1, 75(7), 16811684.[13] Spees, A. M., Wangdi, T., Lopez, C. A., Kingsbury, D. D., Xavier, M. N., Winter, S. E., et al. (2013).Streptomycin-induced inflammation enhances Escherichia coli gut colonization through nitraterespiration. MBio., Jul 2, 4(4).[14] Mayer, B. T., Srinivasan, S., Fiedler, T. L., Marrazzo, J. M., Fredricks, D. N., and Schiffer, J. T. (2015).Rapid and profound shifts in the vaginal microbiota following antibiotic treatment for bacterialvaginosis. J Infect Dis., Sep 1, 212(5), 793802.[15] Casalini, G., Giacomelli, A., Ridolfo, A., Gervasoni, C., and Antinori, S. (2021). Invasive FungalInfections Complicating COVID-19: A Narrative Review. J Fungi (Basel)., Oct 29, 7(11).[16] Baddley, J. W., and Forrest, G. N. (2019). AST Infectious Diseases Community of Practice.Cryptococcosis in solid organ transplantation-Guidelines from the American Society ofTransplantation Infectious Diseases Community of Practice. Clin Transplant., Sep, 33(9), e13543.[17] de Macedo, P. M., Freitas, D. F. S., Varon, A. G., Lamas, C. da C., Ferreira, L. C. F., Freitas, A.dAvila, et al. (2020). COVID-19 and acute juvenile paracoccidioidomycosis coinfection.PLoS Negl Trop Dis., Aug 10, 14(8), e0008559.[18] Kousha, M., Tadi, R., and Soubani, A. O. (2011). Pulmonary aspergillosis: a clinical review.Eur Respir Rev., Sep 1, 20(121), 156174.[19] Jeong, W., Keighley, C., Wolfe, R., Lee, W. L., Slavin, M. A., Kong, D. C. M., et al. (2019). Theepidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis ofcase reports. Clin Microbiol Infect., Jan, 25(1), 2634.[20] Aslam, S., and Rotstein, C. (2019). AST Infectious Disease Community of Practice. Candida infectionsin solid organ transplantation: Guidelines from the American Society of Transplantation InfectiousDiseases Community of Practice. Clin Transplant., Sep, 33(9), e13623.[21] Tissot, F., Agrawal, S., Pagano, L., Petrikkos, G., Groll, A. H., Skiada, A., et al. (2017). ECIL-6guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia andhematopoietic stem cell transplant patients. Haematologica., Mar, 102(3), 433444.[22] Launay, O., Lortholary, O., Bouges-Michel, C., Jarrousse, B., Bentata, M., and Guillevin, L. (1998).Candidemia: a nosocomial complication in adults with late-stage AIDS.Clin Infect Dis., May, 26(5), 11341141.[23] Henriet, S., Verweij, P. E., Holland, S. M., and Warris, A. (2013). Invasive fungal infections in patientswith chronic granulomatous disease. Adv Exp Med Biol., 764, 2755.[24] Huang, L., Zhang, N., Huang, X., Xiong, S., Feng, Y., Zhang, Y., et al. (2019). Invasive pulmonaryaspergillosis in patients with influenza infection: A retrospective study and review of the literature.Clin Respir J., Apr, 13(4), 202211.[25] Schwartz, I. S. (2020). High rates of influenza-associated invasive pulmonary aspergillosis may not beuniversal: aretrospective cohort study from Alberta, Canada. Clin Infect Dis., Oct 1, 71(7), 17601763.[26] Bhanuprasad, K., Manesh, A., Devasagayam, E., Varghese, L, Cherian, L. M., Kurien, R., et al. (2021).Risk factors associated with the mucormycosis epidemic during the COVID-19 pandemic. Int J InfectDis., Oct, 111, 267270.[27] Poissy, J., Damonti, L., Bignon, A., Khanna, N., Von Kietzell, M., Boggian, K., et al. (2020). Riskfactors for candidemia: a prospective matched case-control study. Crit Care., Mar 18, 24(1), 109.[28] Pakdel, F., Ahmadikia, K., Salehi, M., Tabari, A., Jafari, R., Mehrparvar, G., et al. (2021).Mucormycosis in patients with COVID-19: A cross-sectional descriptive multicentre study from Iran.Mycoses., Oct, 64(10), 12381252.[29] Dupont, D., Menotti, J., Turc, J., Miossec, C., Wallet, F., Richard, J-C., et al. (2021). Pulmonaryaspergillosis in critically ill patients with Coronavirus Disease 2019 (COVID-19).Med Mycol., Jan 4, 59(1), 110114.[30] Salehi, M., Ahmadikia, K., Mahmoudi, S., Kalantari, S., Jamalimoghadamsiahkali, S., Izadi, A., et al.(2020). Oropharyngeal candidiasis in hospitalised COVID-19 patients from Iran: Species identificationand antifungal susceptibility pattern. Mycoses., Aug, 63(8), 771778.[31] Alegre-Gonzlez, D., Herrera, S., Bernal, J., Soriano, A., and Bodro, M. (2021). DisseminatedCryptococcus neoformans infection associated to COVID-19. Med Mycol Case Rep., Dec, 34, 3537.[32] Thyagarajan, R. V., Mondy, K. E., and Rose, D. T. (2021). Cryptococcus neoformans blood streaminfection in severe COVID-19 pneumonia. IDCases., Aug 31, 26, e01274.[33] Gamon, E., Tammena, D., Wattenberg, M., and Augenstein, T. (2021). [Rare superinfection in aCOVID-19 patient-A chronology]. Anaesthesist., 2022 Jan;71(1):38-49. Epub 2021 Aug 24.[34] Gil, Y., Gil, Y. D., and Markou, T. (2021). The Emergence of Cryptococcemia in COVID-19 Infection:A Case Report. Cureus., Nov 20, 13(11), e19761.[35] Thota, D. R., Ray, B., Hasan, M., and Sharma, K. (2022). Cryptococcal Meningoencephalitis DuringConvalescence from Severe COVID-19 Pneumonia. Neurohospitalist., Jan, 12(1), 9699.[36] Khatib, M. Y., Ahmed, A. A., Shaat, S. B., Mohamed, A. S, and Nashwan, A. J. (2021).Cryptococcemia in a patient with COVID-19: A case report. Clin Case Rep., Feb, 9(2), 853855.[37] Traver, E. C., and Malav Snchez, M. (2022). Pulmonary aspergillosis and cryptococcosis as acomplication of COVID-19. Med Mycol Case Rep., Mar, 35, 2225.[38] Karnik, K., Wu, Y., Ruddy, S., Quijano-Rondan, B., Urban, C., Turett, G., et al. (2022). Fatal case ofdisseminated cryptococcal infection and meningoencephalitis in the setting of prolongedglucocorticoid use in a Covid-19 positive patient. IDCases., Jan 6, 27, e01380.[39] RECOVERY Collaborative Group, Horby, P., Lim, W. S., Emberson, J. R., Mafham, M., Bell, J. L.,et al. (2021). Dexamethasone in Hospitalized Patients with Covid-19.N Engl J Med., Feb 25, 384(8), 693704.[40] Clinical Management Summary. NIH COVID-19 Treatment Guidelines [Internet]. [cited 2022 Jan 17];Available from: https://files.covid19treatmentguidelines.nih.gov/guidelines/section/section_100.pdf.[41] Arnow, P. M., Andersen R. L., Mainous P. D., and Smith E. J. (1978). Pumonary aspergillosis duringhospital renovation. Am Rev Respir Dis., Jul, 118(1), 4953.[42] Chazalet, V., Debeaupuis, J. P., Sarfati, J., Lortholary, J., Ribaud, P., Shah, P., et al. (1998). Moleculartyping of environmental and patient isolates of Aspergillus fumigatus from various hospital settings. JClin Microbiol., Jun, 36(6), 14941500.[43] Dewhurst, A. G., Cooper, M. J., Khan, S. M., Pallett, A. P., and Dathan, J. R. (1990). Invasiveaspergillosis in immunosuppressed patients: potential hazard of hospital building work. BMJ., Oct 6,301(6755), 802804.[44] Latg, J. P. (1999). Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev., Apr, 12(2), 310350.[45] Basich, J. E., Graves, T. S., Baz, M. N., Scanlon, G., Hoffmann, R. G., Patterson, R., et al. (1981).Allergic bronchopulmonary aspergillosis in corticosteroid-dependent asthmatics. J Allergy ClinImmunol., Aug, 68(2), 98102.[46] Knutsen, A. P., and Slavin, R. G. (1991). Allergic bronchopulmonary aspergillosis in patients withcystic fibrosis. Clin Rev Allergy., 9(1-2), 103118.[47] Thompson Iii, G. R., Cornely, O. A., Pappas, P. G., Patterson, T. F., Hoenigl, M., Jenks, J. D., et al.(2020). Invasive Aspergillosis as an Under-recognized Superinfection in COVID-19. Open ForumInfect Dis., Jul, 7(7), ofaa242.[48] Bartoletti, M., Pascale, R., Cricca, M., Rinaldi, M., Maccaro A., Bussini, L., et al. (2021).Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: AProspective Study. Clin Infect Dis., Dec 6, 73(11), e3606e3614.[49] Nasri, E., Shoaei, P., Vakili, B., Mirhendi, H., Sadeghi, S., Hajiahmadi, S., et al. (2020). Fatal InvasivePulmonary Aspergillosis in COVID-19 Patient with Acute Myeloid Leukemia in Iran.Mycopathologia., Dec, 185(6), 10771084.[50] Morens, D. M., Taubenberger, J. K., and Fauci, A. S. (2008). Predominant role of bacterial pneumoniaas a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J InfectDis., Oct 1, 198(7), 962970.[51] WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne, J. A. C.,Murthy, S., Diaz, J. V., Slutsky, A. S., Villar, J., et al. (2020). Association Between Administration ofSystemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta analysis.JAMA., Oct 6, 324(13), 13301341.[52] Lamoth, F., Lewis, R. E., Walsh, T. J., and Kontoyiannis, D. P. (2021). Navigating the uncertainties ofCOVID-19 associated aspergillosis (CAPA): A comparison with influenza associated aspergillosis(IAPA). J Infect Dis., Mar 26;[53] Schaffner, A. (1994). Macrophage-Aspergillus interactions. Immunol Ser., 60, 545552.[54] Meier-Osusky, I., Schoedon, G., Bluer, F., Schneemann, M., and Schaffner, A. (1996). Comparisonof the antimicrobial activity of deactivated human macrophages challenged with Aspergillus fumigatusand Listeria monocytogenes. J Infect Dis., Sep, 174(3), 651654.[55] Calar, K., Kalkanc, A., Fidan, I., Aydoan, S., Hzel, K., Dizbay, M., et al. (2011). [Investigation ofinterleukin-10, tumor necrosis factor-alpha and interferon-gamma expression in experimental model ofpulmonary aspergillosis]. Mikrobiyol Bul., Apr, 45(2), 344352.[56] Fu, Y., Cheng, Y., and Wu, Y. (2020). Understanding SARS-CoV-2-Mediated InflammatoryResponses: From Mechanisms to Potential Therapeutic Tools. Virol Sin., Jun, 35(3), 266271.[57] Yu, X., Zhang, X., Zhao, B., Wang, J., Zhu, Z., Teng, Z., et al. (2011). Intensive cytokine induction inpandemic H1N1 influenza virus infection accompanied by robust production of IL-10 and IL-6. PLoSOne., Dec 9, 6(12), e28680.[58] Su, H., Li, C., Wang, Y., Li, Y., Dong, L., Li, L., et al. (2019). Kinetic host defense of the mice infectedwith Aspergillus Fumigatus. Future Microbiol., May, 14, 705716.[59] Meduri, G. U., Headley, S., Kohler, G., Stentz, F., Tolley, E., Umberger, R., et al. (1995). Persistentelevation of inflammatory cytokines predicts a poor outcome in ARDS.Chest., Apr, 107(4), 10621073.[60] Dimopoulos, G., Almyroudi, M. P., Myrianthefs, P. and Rello, J. (2021). COVID-19-AssociatedPulmonary Aspergillosis (CAPA). Journal of Intensive Medicine., Oct, 1(2), 71-80.[61] Verweij, P. E., Oakley, K. L., Morrissey, J., Morrissey, G., and Denning, D. W. (1998). Efficacy ofLY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine modelof invasive aspergillosis. Antimicrob Agents Chemother., Apr, 42(4), 873878.[62] Eichner, R. D., Al Salami, M., Wood, P. R., and Mllbacher, A. (1986). The effect of gliotoxin uponmacrophage function. Int J Immunopharmacol., 8(7), 789797.[63] Chong, W. H., and Neu, K. P. (2021). Incidence, diagnosis and outcomes of COVID-19-associatedpulmonary aspergillosis (CAPA): a systematic review. J Hosp Infect., Jul, 113, 115129.[64] Verweij, P. E., Brggemann, R. J. M., Azoulay, E., Bassetti, M., Blot, S., Buil, J. B., et al. (2021).Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonaryaspergillosis. Intensive Care Med., Aug, 47(8), 819834.[65] Van Biesen, S., Kwa, D., Bosman, R. J., and Juffermans, N. P. (2020). Detection of Invasive PulmonaryAspergillosis in COVID-19 with Non-directed Bronchoalveolar Lavage.Am J Respir Crit Care Med., Jul 15.[66] Chong, G-L. M., van de Sande, W. W. J., Dingemans, G. J. H., Gaajetaan, G. R., Vonk, A. G., Hayette,M-P., et al. (2015). Validation of a new Aspergillus real-time PCR assay for direct detection ofAspergillus and azole resistance of Aspergillus fumigatus on bronchoalveolar lavage fluid. J ClinMicrobiol., Mar, 53(3), 868874.[67] Costantini, C., van de Veerdonk, F. L., and Romani, L. (2020). Covid-19-Associated PulmonaryAspergillosis: The Other Side of the Coin. Vaccines (Basel). Dec 1, 8(4).[68] Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., et al. (2020). Epidemiological and clinicalcharacteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.Lancet., Feb 15, 395(10223), 507513.[69] Alanio, A., Dellire, S., Fodil, S., Bretagne, S., and Mgarbane, B. (2020). Prevalence of putativeinvasive pulmonary aspergillosis in critically ill patients with COVID-19.Lancet Respir Med., Jun, 8(6), e48e49.[70] Nguyen, L. S., Dolladille, C., Drici, M-D., Fenioux, C., Alexandre, J., Mira, J. P., et al. (2020).Cardiovascular toxicities associated with hydroxychloroquine and azithromycin: an analysis of theworld health organization pharmacovigilance database. Circulation., Jul 21, 142(3), 303305.[71] Tabassum, T., Araf, Y., Moin, A. T., Rahaman, T. I., and Hosen, M. J. (2021). COVID-19-associatedmucormycosis: possible role of free iron uptake and immunosuppression.Mol Biol Rep., 49(1):747-754 Oct 28.[72] Farmakiotis, D., and Kontoyiannis, D. P. (2016). Mucormycoses. Infect Dis ClinNorth Am., Mar, 30(1), 143163.[73] Skiada, A., Pagano, L., Groll, A., Zimmerli, S., Dupont, B., Lagrou, K., et al. (2011). Zygomycosis inEurope: analysis of 230 cases accrued by the registry of the European Confederation of MedicalMycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect.,Dec 1, 17(12), 18591867.[74] Divakar, P. K. (2021). Fungal Taxa Responsible for Mucormycosis/Black Fungusamong COVID 19 Patients in India. J Fungi (Basel). Aug 7, 7(8).[75] Colombo, A. (2021). Micoses Emergentes e Reemergentes relacionadas ao SARS-CoV-2. IV Simposio:Infeccoes Emergentes e Reemergentes no Brasil; Mar 9. [Emerging and Reemerging Mycoses Relatedto SARS-CoV-2. IV Symposium: Emerging and Reemerging Infections in Brazil; Mar 9].[76] Agoramoorthy, G. (2021). Indias Second Wave of Coronavirus Disease 2019 (COVID-19) and theLethal Outbreak of Black Fungus Infection. Arch Pathol Lab Med., Jul 29. 145(10):1191-1192.[77] IDF Atlas 9th edition and other resources [Internet]. [cited 2021 Sep 5]. Available from:https://www.diabetesatlas.org/en/resources/.[78] Pal, R., Singh, B., Bhadada, S. K., Banerjee, M., Bhogal, R. S., Hage, N, et al. (2021). COVID-19-associated mucormycosis: An updated systematic review of literature. Mycoses., Dec;64(12):1452-1459. Epub 2021 Jun 16.[79] Mller, J. A., Gro, R., Conzelmann, C., Krger, J., Merle, U., Steinhart, J., et al. (2021).SARS-CoV 2 infects and replicates in cells of the human endocrine and exocrine pancreas.Nat Metab., Feb 3, 3(2), 149165.[80] Ellingsgaard, H., Hauselmann, I., Schuler, B., Habib, A. M., Baggio, L. L., Meier, D. T., et al. (2011).Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cellsand alpha cells. Nat Med., Oct 30, 17(11), 14811489.[81] Costela-Ruiz, V. J., Illescas-Montes, R., Puerta-Puerta, J. M., Ruiz, C., and Melguizo-Rodrguez, L.(2020). SARS-CoV-2 infection: The role of cytokines in COVID-19 disease.Cytokine Growth Factor Rev., Aug, 54, 6275.[82] Chiasson, J. L., Aris-Jilwan, N., Blanger, R., Bertrand, S., Beauregard, H., Eko, J. M., et al. (2003).Diagnosis and treatment of diabetic ketoacidosis and the hyperglycemic hyperosmolar state. Can MedAssoc J., Apr 1, 168(7), 859866.[83] Anand, V. K., Alemar, G., and Griswold, J. A. (1992). Intracranial complications of mucormycosis: anexperimental model and clinical review. Laryngoscope., Jun, 102(6), 656662.[84] Gebremariam, T., Liu, M., Luo, G., Bruno, V., Phan, Q. T., Waring, A. J., et al. (2014). CotH3 mediatesfungal invasion of host cells during mucormycosis. J Clin Invest., Jan, 124(1), 237250.[85] Roilides, E., Antachopoulos, C., and Simitsopoulou, M. (2014). Pathogenesis and host defence againstMucorales: the role of cytokines and interaction with antifungal drugs. Mycoses., Dec, 57 Suppl 3, 4047.[86] Gebremariam, T., Lin, L., Liu, M., Kontoyiannis, D. P., French, S., Edwards, J. E., et al. (2016).Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis.J Clin Invest., Jun 1, 126(6), 22802294.[87] Chinn, R. Y., and Diamond, R. D. (1982). Generation of chemotactic factors by Rhizopus oryzae inthe presence and absence of serum: relationship to hyphal damage mediated by human neutrophils andeffects of hyperglycemia and ketoacidosis. Infect Immun., Dec, 38(3), 11231129.[88] Shirazi, F., and Kontoyiannis, D. P., Ibrahim, A. S. (2015). Iron starvation induces apoptosis inRhizopus oryzae in vitro. Virulence., 6(2), 121126.[89] Ibrahim, A. S., Spellberg, B., and Edwards, J. (2008). Iron acquisition: a novel perspective onmucormycosis pathogenesis and treatment. Curr Opin Infect Dis., Dec, 21(6), 620625.[90] Camaschella, C., Nai, A., and Silvestri, L. (2020). Iron metabolism and iron disorders revisited in thehepcidin era. Haematologica., Jan 31, 105(2), 260272.[91] Takami, T., and Sakaida, I. (2011). Iron regulation by hepatocytes and free radicals.J Clin Biochem Nutr., Mar, 48(2), 103106.[92] Petrikkos, G., and Tsioutis, C. (2018). Recent advances in the pathogenesis of mucormycoses.Clin Ther., Jun, 40(6), 894902.[93] Lukins, M. B., and Manninen, P. H. (2005). Hyperglycemia in patients administered dexamethasonefor craniotomy. Anesth Analg., Apr, 100(4), 11291133.[94] Perez, A., Jansen-Chaparro, S., Saigi, I., Bernal-Lopez, M. R., Miambres, I., and Gomez-Huelgas, R.(2014). Glucocorticoid-induced hyperglycemia. J Diabetes., Jan, 6(1), 920.[95] Thaiss, C. A., Levy, M., Grosheva, I., Zheng, D., Soffer, E., Blacher, E., et al. (2018). Hyperglycemiadrives intestinal barrier dysfunction and risk for enteric infection. Science.,Mar 23, 359(6382), 13761383.[96] Banerjee, M., and Pal, R., Bhadada, S. K. (2021). Intercepting the deadly trinity of mucormycosis,diabetes and COVID-19 in India. Postgrad Med J., Jun 8.[97] Rammaert, B., Lanternier, F., Zahar, J-R., Dannaoui, E., Bougnoux, M. E., Lecuit, M., et al. (2012).Healthcare-associated mucormycosis. Clin Infect Dis., Feb 1, 54 Suppl 1, S4454.[98] Choksi, T., Agrawal, A., Date, P., Rathod, D., Gharat, A., Ingole, A., et al. (2021). CumulativeMortality and Factors Associated with Outcomes of Mucormycosis After COVID-19 at aMultispecialty Tertiary Care Center in India. JAMA Ophthalmol., Dec 9. 140(1):66-72.[99] Kullberg, B. J., and Arendrup, M. C. (2015). Invasive Candidiasis.N Engl J Med., Oct 8, 373(15), 14451456.[100] Pappas, P. G., Lionakis, M. S., Arendrup, M. C., Ostrosky-Zeichner, L., and Kullberg, B. J. (2018).Invasive candidiasis. Nat Rev Dis Primers., May 11, 4, 18026.[101] Ben-Ami, R., Berman, J., Novikov, A., Bash, E., Shachor-Meyouhas, Y., Zakin, S., et al. (2017).Multidrug-Resistant Candida haemulonii and C. auris, Tel Aviv, Israel.Emerging Infect Dis., Feb, 23(1).[102] Marra, A. R., Camargo, L. F. A., Pignatari, A. C. C., Sukiennik, T., Behar, P. R. P., Medeiros, E. A.S., et al. (2011). Nosocomial bloodstream infections in Brazilian hospitals: analysis of 2,563 cases froma prospective nationwide surveillance study. J Clin Microbiol., May, 49(5), 18661871.[103] Nucci, M., Barreiros, G., Guimares, L. F., Deriquehem, V. A. S., Castieiras, A. C., and Nour, S. A.(2021). Increased incidence of candidemia in a tertiary care hospital with the COVID-19 pandemic.Mycoses., Feb, 64(2), 152156.[104] Macauley, P., and Epelbaum, O. (2021). Epidemiology and Mycology of Candidaemiain non oncological medical intensive care unit patients in a tertiary center in the United States: Overall analysisand comparison between non-COVID-19 and COVID-19 cases. Mycoses., Jun, 64(6), 634640.[105] de Almeida, J. N., Francisco, E. C., Hagen, F., Brando, I. B., Pereira, F. M., Presta Dias, P. H., et al.(2021). Emergence of Candida auris in Brazil in a COVID-19Intensive Care Unit. J Fungi (Basel). Mar 17, 7(3).[106] Arastehfar, A., Carvalho, A., Nguyen, M. H., Hedayati, M. T., Netea, M. G., Perlin, D. S., et al. (2020).COVID-19-Associated Candidiasis (CAC): An Underestimated Complication in the Absence ofImmunological Predispositions? J Fungi (Basel). Oct 8, 6(4).[107] Chow, N. A., Gade, L., Tsay, S. V., Forsberg, K., Greenko, J. A., Southwick, K. L., et al. (2018).Multiple introductions and subsequent transmission of multidrug-resistant Candida auris in the USA:a molecular epidemiological survey. Lancet Infect Dis., Dec, 18(12), 13771384.[108] Azoulay, E., Timsit, J-F., Tafflet, M., de Lassence, A., Darmon, M., Zahar, J. R., et al. (2006). Candidacolonization of the respiratory tract and subsequent pseudomonasventilator-associated pneumonia. Chest., Jan, 129(1), 110117.[109] Prestel, C., Anderson, E., Forsberg, K., Lyman, M., de Perio, M. A., Kuhar, D., et al. (2021). Candidaauris Outbreak in a COVID-19 Specialty Care Unit Florida, July-August 2020.MMWR Morb Mortal Wkly Rep., Jan 15, 70(2), 5657.[110] Nobrega de Almeida, J., Brando, I. B., Francisco, E. C., de Almeida, S. L. R., de Oliveira Dias, P.,Pereira, F. M., et al. (2021). Axillary Digital Thermometers uplifted a multidrug-susceptible Candidaauris outbreak among COVID-19 patients in Brazil. Mycoses., Sep, 64(9), 10621072.[111] LAC DPH Health Advisory: Resurgence of Candida auris in Los Angeles County. Key Messages.[112] Ziegler, C. G. K., Allon, S. J., Nyquist, S. K., Mbano, I. M., Miao, V. N., Tzouanas, C. N., et al. (2020).SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells andIs Detected in Specific Cell Subsets across Tissues. Cell., May 28, 181(5), 10161035.e19.[113] Wang, W., Xu, Y., Gao, R., Lu, R., Han, K., Wu, G., et al. (2020). Detection of SARS-CoV-2 inDifferent Types of Clinical Specimens. JAMA., May 12, 323(18), 18431844.[114] Lamers, M. M., Beumer, J., van der Vaart, J., Knoops, K., Puschhof, J., Breugem, T. I., et al. (2020).SARS-CoV-2 productively infects human gut enterocytes. Science., Jul 3, 369(6499), 5054.[115] Kim, H. S. (2021). Do an Altered Gut Microbiota and anAssociated Leaky Gut Affect COVID-19 Severity? MBio., Jan 12, 12(1).[116] Effenberger, M., Grabherr, F., Mayr, L., Schwaerzler, J., Nairz, M., Seifert, M., et al. (2020). Faecalcalprotectin indicates intestinal inflammation in COVID-19. Gut., Aug, 69(8), 15431544.[117] Kayaaslan, B., Eser, F., Kaya Kalem, A., Bilgic, Z., Asilturk, D., Hasanoglu, I., et al. (2021).Characteristics of candidemia in COVID-19 patients; increased incidence, earlier occurrence andhigher mortality rates compared to non-COVID-19 patients. Mycoses., Sep, 64(9), 10831091.[118] Arastehfar, A., Shaban, T., Zarrinfar, H., Roudbary, M., Ghazanfari, M., Hedayati, M. T., et al. (2021).Candidemia among Iranian Patients with Severe COVID-19 Admitted to ICUs. J Fungi (Basel). Apr 8, 7(4).[119] Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ellis, D., Tullio, V., et al. (2010). Resultsfrom the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysisof susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSIstandardized disk diffusion. J Clin Microbiol., Apr, 48(4), 13661377.[120] Sanguinetti, M., Posteraro, B., and Lass-Flrl, C. (2015). Antifungal drug resistance among Candidaspecies: mechanisms and clinical impact. Mycoses., Jun, 58 Suppl 2, 213.[121] Ostrowsky, B., Greenko, J., Adams, E., Quinn, M., OBrien, B., Chaturvedi, V., et al. (2020). Candidaauris Isolates Resistant to Three Classes of Antifungal Medications New York, 2019. MMWR MorbMortal Wkly Rep., Jan 10, 69(1), 69.[122] Beyda, N. D., John, J., Kilic, A., Alam, M. J., Lasco, T. M., and Garey, K. W. (2014). FKS mutantCandida glabrata: risk factors and outcomes in patients with candidemia.Clin Infect Dis., Sep 15, 59(6), 819825.[123] Posteraro, B., Torelli, R., Vella, A., Leone, P. M., De Angelis, G., De Carolis, E., et al. (2020).Pan Echinocandin-Resistant Candida glabrata Bloodstream InfectionComplicating COVID-19: A Fatal Case Report. J Fungi (Basel). Sep 6, 6(3).
Chapters
